GTEx AdiposeTissue 20-29 vs 70-79 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx AdiposeTissue 20-29 vs 70-79 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx AdiposeTissue 20-29 vs 70-79 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx AdiposeTissue 20-29 vs 70-79 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx AdiposeTissue 20-29 vs 70-79 Down.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 1291

Gene

lung cancer associated transcript 1

Gene

cytokine receptor like factor 2

Gene

MT-ND4 pseudogene 12

Gene

MT-CO1 pseudogene 12

Gene

miR-17-92a-1 cluster host gene

Gene

MT-ND1 pseudogene 23

Gene

NOC2 like nucleolar associated transcriptional repressor pseudogene 1

Gene

SH3PXD2A antisense RNA 1

Gene

metallothionein 1J, pseudogene

  • Gene

    long intergenic non-protein coding RNA 1291


  • Gene

    lung cancer associated transcript 1


  • Gene

    cytokine receptor like factor 2


  • Gene

    MT-ND4 pseudogene 12


  • Gene

    MT-CO1 pseudogene 12


  • Gene

    miR-17-92a-1 cluster host gene


  • Gene

    MT-ND1 pseudogene 23


  • Gene

    NOC2 like nucleolar associated transcriptional repressor pseudogene 1


  • Gene

    SH3PXD2A antisense RNA 1


  • Gene

    metallothionein 1J, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.